Cover Page
The handle http://hdl.handle.net/1887/77519 holds various files of this Leiden University dissertation.
Author: Boers, C.B.
Towards
a patient-driven approach
to adverse events of targeted agents
in oncology
The research presented in this dissertation was performed at the Department of Medical Oncology of Leiden University Medical Center, Leiden, The Netherlands, and the Waterland Hospital, Purmerend, The Netherlands.
The research described in this thesis was funded by Amgen, Bayer, EUSA Pharma, GlaxoSmithKline, Novartis, Pfizer, Roche, and the Impaqtt Foundation.
Financial Support for the publication of this dissertation was provided by the Leiden University Medical Center, and support of Gildeprint.
Cover design Monica Schokkenbroek Layout Christine B. Boers-Doets Printed by Gildeprint
ISBN 978-94-93117-00-6
© 2019 Impaqtt, the CancerMed Adverse Event Research & Valorisation Foundation
Towards
a patient-driven approach
to adverse events of targeted agents
in oncology
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties te verdedigen op woensdag 4 september 2019
klokke 16:15 uur
door
Christine Bettine Boers
Promotores Prof. dr. A.J. Gelderblom Prof. dr. A.A. Kaptein
Copromotor Dr. J.B. Epstein, City of Hope, Duarte, CA, United States
Promotiecommissie Prof. dr. J.J.M. van der Hoeven, LUMC Prof. dr. W.T.A. van der Graaf, NKI/Radboud Dr. J.R. Kroep, LUMC
Contents
01 | General introduction ... 1
02 | Oral Adverse Events Associated With Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review. Oncologist 2011;17(1):135-44. ... 11
03 | Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013 Dec;9(12):1883-92. ... 29
04 | Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol (2015) 26 (suppl 5): v139-v151. ... 45
05 | Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016 Feb;24(2):513-521. ... 71
06 | Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. Eur J Oncol Nurs. 2013;17:802-7. ... 87
07 | Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer, 2013. 21(7): p. 1919-26. ..101
08 | General discussion, summary & future perspectives ...115
General discussion and summary ...115
Future perspectives ...122
References ...131
09 | Samenvatting (Summary in Dutch) ...137
10 | About the author ...139
Curriculum Vitae ...139
List of publications ...140
